Tag: clinical-stage company

August 26, 2018

5 Top Weekly NASDAQ Biotech Stocks: Bellerophon Leads the Pack

Bellerophon Therapeutics, Chiasma, BioLife Solutions, Cerecor and MiMedx Group were last week's top gainers on the NASDAQ Biotechnology Index.
August 12, 2018

5 Top Weekly NASDAQ Biotech Stocks: Vericel Takes Top Spot

Vericel, AcelRx, Tetraphase Pharmaceuticals, KalVista and Infinity Pharmaceuticals were last week's top gainers on the NASDAQ Biotechnology Index.
July 29, 2018

5 Top Weekly NASDAQ Biotech Stocks: resTORbio Leads the Pack

resTORbio, ADMA Biologics, Misonix, Novus Therapeutics and Innovate Biopharmaceuticals were last week's top gainers on the NASDAQ Biotechnology Index.
July 15, 2018

5 Top Weekly NASDAQ Biotech Stocks: Arbutus on Top

Adamis Pharmaceutical, Juniper Pharmaceuticals, Anavex Life Sciences, Arbutus BioPharma and Soleno Therapeutics were last week's top gainers on the NASDAQ...
June 10, 2018

5 Top Weekly NASDAQ Biotech Stocks: MEI Pharma on Top

MEI Pharma, Anavex Life Sciences, Trillium Therapeutics, Celldex Therapeutics and Ophthotech were last week's top gainers on the NASDAQ Biotechnology...
May 13, 2018

5 Top Weekly NASDAQ Biotech Stocks: Helius Up 43.19 Percent

Helius Medical Technologies, vTv Therapeutics, Second Sight Medical Products, Depomed and Senomyx were last week's top gainers on the NASDAQ.
May 7, 2018

Auris Medical Receives Positive Scientific Advice from EMA on Development Plan and Regulatory Pathway for AM-111

Auris Medical (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, announced today...
April 29, 2018

5 Top Weekly NASDAQ Biotech Stocks: Eleven Biotherapeutics Up 45 Percent

Eleven Biotherapeutics, EyePoint Pharmaceuticals, Avid Bioservices, Cerecor and Celldex were last week's top gainers on the NASDAQ.
April 20, 2018

Clementia Initiates Phase 2 MO-Ped Trial for Palovarotene in Patients with Multiple Osteochondromas

Clementia Pharmaceuticals (NASDAQ:CMTA), a clinical-stage company innovating new treatments for people with ultra-rare bone disorders and other diseases, today announced the...
April 10, 2018

Epizyme Announces Publication of Tazemetostat Phase 1 Clinical Data in The Lancet Oncology

Epizyme (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, announced today its first-in-human data on the effects of EZH2 inhibition...